Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

[Local monitoring center for clozapine (Leponex) treatment].

Bakken K, Bratlid T, Erlandsen C, Lingjaerde O, Nome S.

Tidsskr Nor Laegeforen. 1998 Mar 10;118(7):1076-8. Norwegian.

PMID:
9531833
2.

Clozapine: the commitment to patient safety.

Alphs LD, Anand R.

J Clin Psychiatry. 1999;60 Suppl 12:39-42. Review.

3.

Clozapine treatment in Australia: a review of haematological monitoring.

Copolov DL, Bell WR, Benson WJ, Keks NA, Strazzeri DC, Johnson GF.

Med J Aust. 1998 May 18;168(10):495-7.

PMID:
9631674
4.
5.

Clozapine-induced intestinal occlusion: a serious side effect.

Pelizza L, De Luca P, La Pesa M, Borella D.

Acta Biomed. 2007 Aug;78(2):144-8.

PMID:
17933283
6.

Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme.

Hill GR, Harrison-Woolrych M.

N Z Med J. 2008 Oct 3;121(1283):68-75.

PMID:
18841187
7.

Monitoring the safe use of clozapine: a consensus view from Victoria, Australia.

Berk M, Fitzsimons J, Lambert T, Pantelis C, Kulkarni J, Castle D, Ryan EW, Jespersen S, McGorry P, Berger G, Kuluris B, Callaly T, Dodd S.

CNS Drugs. 2007;21(2):117-27. Review.

PMID:
17284094
8.

Fatal venous thromboembolism associated with antipsychotic therapy.

Farah RE, Makhoul NM, Farah RE, Shai MD.

Ann Pharmacother. 2004 Sep;38(9):1435-8. Epub 2004 Jul 27.

PMID:
15280515
9.

Development of a method of clozapine dosage by selective electrode to the iodides.

Teyeb H, Douki W, Najjar MF.

Drug Chem Toxicol. 2012 Jul;35(3):272-6. doi: 10.3109/01480545.2011.598534. Epub 2011 Sep 22.

PMID:
21939364
10.

Myocarditis due to clozapine.

[No authors listed]

Prescrire Int. 2001 Jun;10(53):83.

PMID:
11718172
11.

[Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].

Bret P, Jolivel C, Bret MC, Veylit S, Martin C, Garcia P.

Encephale. 1998 Jul-Aug;24(4):365-77. French.

PMID:
9809242
12.

[Leponex, 10 years after -- a clinical review].

Llorca PM, Pere JJ.

Encephale. 2004 Sep-Oct;30(5):474-91. Review. French.

PMID:
15627052
13.

Development of the Clozaril Patient Management System.

Bastani B, Alphs LD, Meltzer HY.

Psychopharmacology (Berl). 1989;99 Suppl:S122-5.

PMID:
2813664
14.

Clozapine--a dangerous drug in a clozapine-naïve subject.

Stanworth D, Hunt NC, Flanagan RJ.

Forensic Sci Int. 2012 Jan 10;214(1-3):e23-5. doi: 10.1016/j.forsciint.2011.07.032. Epub 2011 Aug 9.

PMID:
21831547
15.

Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.

Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J.

J Clin Psychiatry. 1998;59 Suppl 3:3-7. Review.

17.

Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring.

Schulte P.

Ann Pharmacother. 2006 Apr;40(4):683-8. Epub 2006 Mar 7.

PMID:
16595571
18.

Serum level of clozapine and relapse.

Ulrich S, Wolf R, Staedt J.

Ther Drug Monit. 2003 Apr;25(2):252-5.

PMID:
12657924
19.

A clozapine overdose with markedly elevated serum levels.

Mahoney MC, Connolly BF, Smith CM.

J Clin Pharmacol. 1999 Jan;39(1):97-100.

PMID:
9987706
20.

Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy.

Patel NC, Crismon ML, Miller AL, Johnsrud MT.

Pharmacotherapy. 2005 Sep;25(9):1242-7.

PMID:
16164397

Supplemental Content

Support Center